Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,807

Document Document Title
WO/2018/166493A1
A heteroaryl[4,3-c]pyrimidin-5-amine derivative, a preparation method therefor, and medical uses thereof. Specifically, a heteroarylo[4,3-c]pyrimidin-5-amine derivative represented by a general formula (I), a preparation method therefor,...  
WO/2018/167629A1
The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates ther...  
WO/2018/165718A1
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...  
WO/2018/168292A1
The purpose of the present invention is to provide: an organic EL element material and a compound, each of which has high luminous efficiency; and an organic EL element, a display device and a lighting device, in each of which the organi...  
WO/2018/167315A2
Disclosed herein are compositions of a deep eutectic solvent with a host, such as a supramolecular host, and the use of the composition to form a composition comprising the host in complex with one or more guests. The deep eutectic solve...  
WO/2018/170236A1
The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPKl) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. fal...  
WO/2018/167276A1
The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use ...  
WO/2018/167652A1
The present invention provides a process for the preparation of amorphous form of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]met hyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4yl- methyl)-amino]-phenyl}sulfonyl)-2...  
WO/2018/170078A1
An aryl-piperidine derivative of formula I, wherein the meaning of R3, X, Cz, and Cy is that specified in the description, for use as inhibitors of T cells.  
WO/2018/167176A1
A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNFα activiy, are accordingly of benefit in the treatment and/or prevention of various ...  
WO/2018/167630A1
The present invention relates to new pyrazolo[l,5-a]pyrimidine derivatives of formula (I) or pharmaceutical ly acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates the...  
WO/2018/168815A1
Provided is a novel and industrially useful method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative. The present invention provides a method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative, ...  
WO/2018/169373A1
The present invention relates to a compound represented by the Chemical Formula 1 defined in the present specification, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used f...  
WO/2018/165979A1
The present invention relates to a crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-d ihydro-4H-pyrrolo[1,2-b]pyrazole (Galunisertib or LY2157299) represented by formula (I). Compared with the known solid form o...  
WO/2018/164191A1
The present invention provides a substituted pyrrolidine compound having orexin receptor type 2 agonist activity. A compound represented by the formula (in the formula, each symbol is as described in the specification) or a salt thereof ...  
WO/2018/162932A1
The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound ...  
WO/2018/165569A1
Disclosed herein are compounds of formula II: II or a salt thereof. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as lung cancer.  
WO/2018/161910A1
Disclosed in the present invention is an aminopyrimidine five-membered heterocyclic compound, and an intermediate, preparation method, pharmaceutical composition and application thereof. The aminopyrimidine five-membered heterocyclic com...  
WO/2018/161871A1
Disclosed is a p53-MDM2 inhibitor compound having the structure of an imidazopyridine, and particularly disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.  
WO/2018/164184A1
Disclosed is a compound selected from among aniline derivatives represented by formula (1) and naphthalene derivatives represented by formula (2), or a salt thereof. (In the formulae, each of R1 and R2 independently represents a hydrogen...  
WO/2018/161876A1
The present invention relates to a dihydroquinoxaline bromodomain recognition protein inhibitor, a preparation method and a use thereof. The inhibitor of the present invention is a compound represented by general formula (I), or a stereo...  
WO/2018/162607A1
The invention relates to compounds of formula I: (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmac...  
WO/2018/157794A1
Disclosed herein are salts of (R) -2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H) -one, and crystalline forms (polymorphs) thereof. Also disclosed herein are methods...  
WO/2018/160022A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure comprises a specific combination of a light-emitting layer and an electron transport zone, thereby pr...  
WO/2018/158298A1
The present invention relates to polymorphic forms of (2R)-N-hydroxy-4-(6-((1-(2- hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrr olo[1,2-c]imidazol-2(3H)-yl)-2- methyl-2-(methylsulfonyl)butanamide.  
WO/2018/160618A1
Substituted hydroquinones, 1,4-quinones, catechols, 1,2-quinones, anthraquinones, and anthrahydroquinones are disclosed herein. The substituted hydroquinones and catechols have the formula: while the substituted 1,4-quinones or 1,2-have ...  
WO/2018/160824A1
The disclosure is directed to compounds of Formula I, Formula II, Formula III, or Formula IV: Methods of their use and preparation are also described.  
WO/2018/159964A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to pro...  
WO/2018/160891A1
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutical...  
WO/2018/158592A1
A process for preparing a tetra-substituted aminobiphenol macrocyclic ligand having the structure (I), comprising the step of treating a precursor compound having the structure (II) with a compound having the structure R6-L where L repre...  
WO/2018/159613A1
Provided is a cancer treatment method that uses a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. An antitumor agent that combines: a pyrazolo[3,4-d]pyrimidine compound represented by general formula (I) (in which X, Y, Z1, Z2, Z3,...  
WO/2018/157801A1
The present invention relates to a cyano group-substituted fused bicyclic derivative, and a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used for inhibiting xanthine oxidase an...  
WO/2018/159766A1
The present invention provides a novel stable phthalocyanine-based compound that has a 20π-electron structure. This compound is represented by general formula (1) (in general formula (1), each Q independently represents an alkyl group h...  
WO/2018/159970A1
The present disclosure relates to an organic electroluminescent device comprising a light-emitting layer and a hole transport zone. By comprising a specific combination of a light-emitting layer and a hole transport zone, it is possible ...  
WO/2018/161033A1
Described herein are IRE1-alpha inhibitors, compositions containing such inhibitors, and methods of treatment of cancer that include administration of such compounds. Exemplary compounds are provided throughout the application.  
WO/2018/157232A1
Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including pros...  
WO/2018/160076A1
Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthriti...  
WO/2018/160855A1
The disclosure is directed to compounds of Formula I, Formula II, Formula III, and Formula IV: (I) (II) (III) (IV) Methods of their use and preparation are also described.  
WO/2018/157830A1
The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositi...  
WO/2018/155916A2
The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein...  
WO/2018/156812A1
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance t...  
WO/2018/153778A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be pr...  
WO/2018/153887A1
The present invention relates to compound III for the use in the treatment of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases like first episode of psychosis (FEP), relapses of these...  
WO/2018/154133A1
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2018/153312A1
Disclosed in the present invention are an azaspiro compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. The azaspiro compound having the structural characteristics of formula (I) of ...  
WO/2018/155469A1
The present invention addresses the problem of providing a diazachlorin analog which causes occurrence of photoluminescence. The diazachlorin analog comprises, in the backbone thereof, partial structures represented by general formulas (...  
WO/2018/154578A1
Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.  
WO/2018/153285A1
Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.  
WO/2018/149231A1
Disclosed is a 7H-pyrrolo[2,3-d]pyrimidine derivative as represented by formula (I). The compound provided by the present invention has a remarkable inhibitory effect on tumour cells and can be used for preventing and/or treating tumour-...  

Matches 1 - 50 out of 36,807